Ключевые слова
Аннотация
Хроническая болезнь почек (ХБП) все чаще признается глобальной проблемой здравоохранения и затрагивает от 10% до 15% населения мира. Сахарный диабет является основной причиной терминальной стадии почечной недостаточности. Более 422 миллионов взрослых в мире живут с сахарным диабетом, у 40% из которых разовьется ХБП. Хроническая болезнь почек является распространенным осложнением и сопутствующим состоянием сахарного диабета. Лечение пациентов с диабетом и хронической болезнью почек, включая интенсивный контроль уровня сахара в крови и артериального давления, было очень похожим для пациентов с диабетом 1-го и 2-го типов. Новые терапевтические цели показали многообещающие результаты и могут привести к более специфическим вариантам лечения для пациентов с диабетом 1-го и 2-го типов.
Библиографические ссылки
United States Renal Data System. 2019 USRDS Annual Data Report Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2019.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in Diabetes-2019. Diabetes Care 2019 42 (Supplement 1) S13–S28. (https://doi.org/10.2337/ dc19-S002)
Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, et al. Pathologic classification of diabetic nephropathy. Journal of the American Society of Nephrology 2010 21 556–563. (https://doi. org/10.1681/ASN.2010010010)
Umanath K & Lewis JB. Update on diabetic nephropathy: core curriculum 2018. American Journal of Kidney Diseases 2018 71 884–895. (https://doi.org/10.1053/j.ajkd.2017.10.026)
Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997 46 (Supplement 2) S104–S111. (https://doi.org/10.2337/diab.46.2.s104)
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014 129 587–597. (https://doi.org/10.1161/CIRCULATIONAHA.113.005081)
Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A & Warram JH. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 2014 37 226–234. (https://doi. org/10.2337/dc13-0985)
Mathisen UD, Melsom T, Ingebretsen OC, Jenssen T, Njølstad I, Solbu MD, Toft I & Eriksen BO. Estimated GFR associates with cardiovascular risk factors independently of measured GFR. Journal of the American Society of Nephrology 2011 22 927–937. (https://doi. org/10.1681/ASN.2010050479)
Tong X, Yu Q, Ankawi G, Pang B, Yang B & Yang H. Insights into the role of renal biopsy in patients with T2DM: a literature review of global renal biopsy results. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders 2020 11 1983–1999. (https://doi.org/10.1007/s13300-020-00888-w)
Sharma SG, Bomback AS, Radhakrishnan J, Herlitz LC, Stokes MB, Markowitz GS & D'Agati VD. The modern spectrum of renal biopsy f indings in patients with diabetes. Clinical Journal of the American Society of Nephrology 2013 8 1718–1724. (https://doi.org/10.2215/ CJN.02510213)
Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, Vikman P, Prasad RB, Aly DM, Almgren P, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet: Diabetes and Endocrinology 2018 6 361–369. (https://doi.org/10.1016/ S2213-8587(18)30051-2)
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, https://ec.bioscientifica.com https://doi.org/10.1530/EC-21-0097 © 2021 The authors Chronic kidney disease in diabetes mellitus 10:5 R157 Rand L & Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993 329 977–986. (https://doi.org/10.1056/ NEJM199309303291401)
Epidemiology of Diabetes Interventions and Complications Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW & Zinman B. Intensive diabetes therapy and glomerular f iltration rate in type 1 diabetes. New England Journal of Medicine 2011 365 2366–2376. (https://doi.org/10.1056/NEJMoa1111732)
King P, Peacock I & Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology 1999 48 643–648. (https://doi. org/10.1046/j.1365-2125.1999.00092.x)
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA & Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. American Journal of Physiology 1981 241 F85–F93. (https://doi.org/10.1152/ajprenal.1981.241.1.F85)
Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000 49 1939–1945. (https://doi. org/10.2337/diabetes.49.11.1939)
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 813–820. (https://doi. org/10.1038/414813a)
Fioretto P & Mauer M. Diabetic nephropathy: diabetic nephropathychallenges in pathologic classification. Nature Reviews: Nephrology 2010 6 508–510. (https://doi.org/10.1038/nrneph.2010.96)
Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996 39 1569–1576. (https://doi.org/10.1007/s001250050616)
American Diabetes Association. 6. Glycemic targets: standards of medical care in Diabetes-2020. Diabetes Care 2020 43 (Supplement 1) S66–S76. (https://doi.org/10.2337/dc20-S006)
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International 2020 98 p1–p115.
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Medicine 2010 27 136–142. (https://doi.org/10.1111/j.14645491.2009.02894.x)